Why PAVmed Soared by 12% on Wednesday

Why PAVmed Soared by 12% on Wednesday

The medical device maker's stock rose by over 12% on the back of a key appointment to the board of directors of its most important subsidiary. Lapidus has been tapped to be vice chairman of the board of Lucid Diagnostics, the home of PAVmed's core suite of cancer testing products. The Exact Sciences leading light and healthcare industry veteran is no stranger to PAVmed.